ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS | REFER A PATIENT
Menu
For more information about the Roads Trial, please email us at clinicalaffairs@gtmedtech.com
To locate the nearest enrolling site for you, refer to the participating hospital map
The ROADS Study is sponsored by GT Medical Technologies, Inc., the makers of GammaTile. Please discuss the risks and benefits of participating in this clinical study with your care team.
Indications
GammaTile is indicated to deliver radiation therapy in patients with newly diagnosed malignant and recurrent brain tumors. Possible complications can occur with any neurosurgical procedure and include cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation. For full product and safety information, speak to your physician and refer to the instructions for use.
ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS
ENROLLING NOW
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.